| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/08830180500379655 |
| P698 | PubMed publication ID | 16318989 |
| P2093 | author name string | Lawrence Steinman | |
| Paulo Fontoura | |||
| Hideki Garren | |||
| P2860 | cites work | Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial | Q57911995 |
| Various Types of Acquired Resistance to Experimental ‘Allergic’ Encephalomyelitis | Q58938381 | ||
| T-cell recognition of an immuno-dominant myelin basic protein epitope in multiple sclerosis | Q59049915 | ||
| Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells | Q59078526 | ||
| ENCEPHALOMYELITIS ACCOMPANIED BY MYELIN DESTRUCTION EXPERIMENTALLY PRODUCED IN MONKEYS | Q24681983 | ||
| Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein | Q27765717 | ||
| DNA vaccines: immunology, application, and optimization* | Q28145651 | ||
| Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event | Q28186287 | ||
| The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease | Q28207482 | ||
| Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion | Q28253124 | ||
| Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications | Q28282507 | ||
| Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis | Q28293364 | ||
| OBSERVATIONS ON ATTEMPTS TO PRODUCE ACUTE DISSEMINATED ENCEPHALOMYELITIS IN MONKEYS | Q29543028 | ||
| Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination | Q29614990 | ||
| Axonal transection in the lesions of multiple sclerosis | Q29615585 | ||
| Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis | Q29620481 | ||
| DNA vaccines against human immunodeficiency virus type 1. | Q30342130 | ||
| Encephalitogenic protein: structure | Q30411289 | ||
| Immunomodulation by the copolymer glatiramer acetate | Q30888770 | ||
| Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis | Q33180102 | ||
| Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. | Q33565842 | ||
| Assessment of animal models for MS and demyelinating disease in the design of rational therapy | Q33792972 | ||
| Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis | Q33819182 | ||
| Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. | Q33842739 | ||
| Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein | Q33909604 | ||
| Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. | Q33941343 | ||
| DNA vaccines: a key for inducing long-term cellular immunity | Q33970997 | ||
| Toll meets bacterial CpG-DNA. | Q34260232 | ||
| Assuring the quality, safety, and efficacy of DNA vaccines | Q34275654 | ||
| The regulation of DNA vaccines | Q34280291 | ||
| Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins | Q34323651 | ||
| DNA vaccination in the treatment of autoimmune disease | Q34494439 | ||
| CpG motifs in bacterial DNA and their immune effects | Q34542287 | ||
| Degeneracy, as opposed to specificity, in immunotherapy | Q34551385 | ||
| Oligoclonal bands and antibody responses in multiple sclerosis | Q34609976 | ||
| Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. | Q34674896 | ||
| Allergic encephalomyelitis in monkeys induced by a peptide from the A1 protein | Q34692781 | ||
| Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials | Q34725775 | ||
| Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis | Q34991509 | ||
| C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis | Q35126948 | ||
| Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis | Q35150296 | ||
| Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells | Q35160777 | ||
| Future immunotherapies in multiple sclerosis. | Q35190238 | ||
| Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. | Q35485799 | ||
| Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. | Q35769109 | ||
| Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines | Q35861182 | ||
| Current issues in the treatment of human diseases by mucosal tolerance | Q36024851 | ||
| Design of effective immunotherapy for human autoimmunity | Q36148416 | ||
| Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab | Q36148448 | ||
| Suppression of experimental "allergic" encephalomyelitis in guinea pigs by encephalitogenic proteins extracted from homologous brain | Q36264930 | ||
| Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis | Q36362874 | ||
| Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production | Q36364188 | ||
| Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis | Q36365105 | ||
| A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease | Q36366545 | ||
| Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex | Q36368410 | ||
| Optic Neuritis, A New Variant of Experimental Encephalomyelitis, A Durable Model for All Seasons, Now In Its Seventieth Year | Q36370956 | ||
| A targeted DNA vaccine encoding fas ligand defines its dual role in the regulation of experimental autoimmune encephalomyelitis | Q37267473 | ||
| Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients | Q37356987 | ||
| Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms | Q37415917 | ||
| Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells | Q37415936 | ||
| A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis | Q37611832 | ||
| Amino acid variations at a single residue in an autoimmune peptide profoundly affect its properties: T-cell activation, major histocompatibility complex binding, and ability to block experimental allergic encephalomyelitis | Q37695185 | ||
| Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand | Q38297270 | ||
| Immunotherapy of multiple sclerosis: where are we? Where should we go? | Q40689207 | ||
| Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor | Q40695678 | ||
| Reactivity pattern and cytokine profile of T cells primed by myelin peptides in multiple sclerosis and healthy individuals | Q40821801 | ||
| Autoreactivity to myelin antigens: myelin/oligodendrocyte glycoprotein is a prevalent autoantigen | Q41691805 | ||
| A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis | Q41728578 | ||
| Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones | Q42011739 | ||
| Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis | Q42063824 | ||
| The Effects of the Injection of Normal Brain Emulsion into Rabbits, with Special Reference to the Aetiology of the Paralytic Accidents of Antirabic Treatment | Q42122963 | ||
| Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? | Q42943930 | ||
| The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease | Q43934617 | ||
| Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. | Q44022556 | ||
| An Immunomodulatory GpG Oligonucleotide for the Treatment of Autoimmunity via the Innate and Adaptive Immune Systems | Q44625295 | ||
| Direct gene transfer into mouse muscle in vivo | Q44656494 | ||
| Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts | Q44816677 | ||
| Oral simvastatin treatment in relapsing-remitting multiple sclerosis | Q44897670 | ||
| T cells responsive to myelin basic protein in patients with multiple sclerosis | Q45150262 | ||
| Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies | Q45245008 | ||
| Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. | Q45997264 | ||
| Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. | Q46007698 | ||
| Immunization with DNA encoding an immunodominant peptide of insulin prevents diabetes in NOD mice | Q46058127 | ||
| Essential chemical requirements for induction of allergic encephalomyelitis | Q46149755 | ||
| Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen | Q46201877 | ||
| Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis | Q46266579 | ||
| Identification of autoantibodies associated with myelin damage in multiple sclerosis | Q46424597 | ||
| Allergic encephalomyelitis: Isolation and characterization of encephalitogenic peptides from the basic protein of bovine spinal cord | Q46450330 | ||
| Production of experimental allergic encephalomyelitis in guinea pigs with fractions isolated from bovine spinal cord and killed tubercle bacilli | Q46460083 | ||
| Prevention of experimental allergic encephalomyelitis in guinea pigs | Q46971336 | ||
| Differential prevention of experimental autoimmune encephalomyelitis with antigen-specific DNA vaccination | Q47395321 | ||
| Protective DNA vaccination against experimental autoimmune encephalomyelitis is associated with induction of IFNbeta | Q47953576 | ||
| Targeting fibroblast growth factor-inducible-14 signaling protects from chronic relapsing experimental autoimmune encephalomyelitis | Q48155188 | ||
| Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer | Q48512932 | ||
| Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis | Q50127386 | ||
| Three-year open protocol continuation study of oral tolerization with myelin antigens in multiple sclerosis and design of a phase III pivotal trial. | Q51035638 | ||
| Protection against experimental allergic encephalomyelitis. | Q54028549 | ||
| Experimental Allergic Encephalomyelitis: Synthesis of Disease-Inducing Site of the Basic Protein | Q54058048 | ||
| Suppression of the Immune Response: Reversal of the Disease State with Antigen in Allergic Encephalomyelitis | Q54711484 | ||
| Acquired resistance to experimental allergic encephalomyelitis. | Q54732392 | ||
| Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis | Q57767625 | ||
| P433 | issue | 5-6 | |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 415-446 | |
| P577 | publication date | 2005-09-01 | |
| P1433 | published in | International Reviews of Immunology | Q6052764 |
| P1476 | title | Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides | |
| P478 | volume | 24 |
| Q35745446 | A Distinct Region in Erythropoietin that Induces Immuno/Inflammatory Modulation and Tissue Protection |
| Q46135704 | Anaphylaxis to a self-peptide in the absence of mast cells or histamine |
| Q37051562 | Antigen-specific tolerogenic and immunomodulatory strategies for the treatment of autoimmune arthritis |
| Q50937116 | CRYAB modulates the activation of CD4+ T cells from relapsing-remitting multiple sclerosis patients. |
| Q37590340 | DNA vaccines for autoimmune diseases |
| Q37971623 | Development and deployment of antigen arrays for investigation of B-cell fine specificity in autoimmune disease |
| Q36958305 | Gene vaccination for the induction of immune tolerance. |
| Q38083041 | Immunotherapy of multiple sclerosis: the state of the art. |
| Q36803838 | Inhibitory peptide analogs derived from a major uveitogenic epitope protect from antiretinal autoimmunity by inducing type 2 and regulatory T cells |
| Q30495158 | Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system. |
| Q46616003 | Oral administration of different forms of a tolerogenic peptide to define the preparations and doses that delay anti-DNA antibody production and nephritis and prolong survival in SLE-prone mice |
| Q37107624 | Targeting myelin proteolipid protein to the MHC class I pathway by ubiquitination modulates the course of experimental autoimmune encephalomyelitis. |
| Q36735396 | Technology insight: can autoantibody profiling improve clinical practice? |
| Q34582895 | The immunological basis for treatment of multiple sclerosis |
| Q38627998 | The role of lymphocytes in the development and treatment of alopecia areata |
| Q80434989 | [Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis] |
Search more.